Erasca (ERAS) Stock Forecast, Price Target & Predictions
ERAS Stock Forecast
Erasca stock forecast is as follows: an average price target of $6.00 (represents a 136.22% upside from ERAS’s last price of $2.54) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
ERAS Price Target
ERAS Analyst Ratings
Buy
Erasca Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 18, 2024 | Maury Raycroft | Jefferies | $6.00 | $2.40 | 150.00% | 136.22% |
Apr 01, 2024 | Chris Shibutani | Goldman Sachs | $7.00 | $2.21 | 216.74% | 175.59% |
Erasca Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 1 | 2 |
Avg Price Target | $6.00 | $6.00 | $6.50 |
Last Closing Price | $2.54 | $2.54 | $2.54 |
Upside/Downside | 136.22% | 136.22% | 155.91% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 18, 2024 | Jefferies | Buy | Initialise | |
Aug 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
May 20, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Apr 01, 2024 | Goldman Sachs | Buy | Buy | Hold |
Feb 03, 2023 | Morgan Stanley | Overweight | Upgrade |
Erasca Financial Forecast
Erasca Revenue Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
# Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Erasca EBITDA Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Erasca Net Income Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-84.53M | $-81.49M | $-75.29M | $-72.23M | $-78.29M | $-75.47M | $-69.73M | $-66.89M | $-45.18M | $-41.79M | $-40.66M | $-37.84M | $-36.46M | $-47.18M | $-39.87M |
High Forecast | $-84.53M | $-81.49M | $-75.29M | $-72.23M | $-78.29M | $-75.47M | $-69.73M | $-66.89M | $-45.18M | $-41.79M | $-40.66M | $-34.93M | $-33.42M | $-47.18M | $-39.87M |
Low Forecast | $-84.53M | $-81.49M | $-75.29M | $-72.23M | $-78.29M | $-75.47M | $-69.73M | $-66.89M | $-45.18M | $-41.79M | $-40.66M | $-46.57M | $-42.53M | $-47.18M | $-39.87M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Erasca SG&A Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Erasca EPS Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Avg Forecast | $-0.30 | $-0.29 | $-0.27 | $-0.26 | $-0.28 | $-0.27 | $-0.25 | $-0.24 | $-0.16 | $-0.15 | $-0.14 | $-0.13 | $-0.13 | $-0.17 | $-0.18 |
High Forecast | $-0.30 | $-0.29 | $-0.27 | $-0.26 | $-0.28 | $-0.27 | $-0.25 | $-0.24 | $-0.16 | $-0.15 | $-0.14 | $-0.12 | $-0.12 | $-0.17 | $-0.18 |
Low Forecast | $-0.30 | $-0.29 | $-0.27 | $-0.26 | $-0.28 | $-0.27 | $-0.25 | $-0.24 | $-0.16 | $-0.15 | $-0.14 | $-0.16 | $-0.15 | $-0.17 | $-0.18 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Forecast
Erasca Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
KROS | Keros Therapeutics | $18.00 | $102.00 | 466.67% | Buy |
CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
OLMA | Olema Pharmaceuticals | $6.14 | $27.00 | 339.74% | Buy |
IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
SANA | Sana Bio | $1.91 | $8.00 | 318.85% | Buy |
RLAY | Relay Therapeutics | $4.50 | $18.00 | 300.00% | Buy |
ARVN | Arvinas | $19.10 | $58.50 | 206.28% | Buy |
CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
PLRX | Pliant Therapeutics | $14.37 | $35.50 | 147.04% | Buy |
MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
ZNTL | Zentalis Pharmaceuticals | $3.13 | $7.00 | 123.64% | Buy |
STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
DSGN | Design Therapeutics | $6.25 | $9.67 | 54.72% | Buy |
EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |